Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	541.01M +17.1%
Revenue (ttm)	87.70M -14.0%
Net Income	-101.23M
EPS	-4.38
Shares Out	23.12M
PE Ratio	n/a
Forward PE	11.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,129
Average Volume	33,298
Open	23.80
Previous Close	23.40
Day's Range	23.10 - 23.90
52-Week Range	20.50 - 36.00
Beta	0.59
RSI	46.68
Earnings Date	Mar 19, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.